Trial Profile
A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2023
Price :
$35
*
At a glance
- Drugs Cendakimab (Primary) ; Cendakimab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Proof of concept; Therapeutic Use
- Acronyms HEROES
- Sponsors Celgene Corporation; Receptos
- 17 Oct 2023 Results presented at the 31st United European Gastroenterology Week
- 01 Apr 2023 Results of post hoc analysis assessing the dysphagia days as a measure of symptom improvement in patients with eosinophilic esophagitis from the HEROES study, published in the American Journal of Gastroenterology.
- 27 Feb 2023 Results assessing systemic cendakimab administration impact on local esophageal gene expression in a substudy from this trial presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology